What Actually Remains At Cipia: The Economics Of The Aftermarket Tail After The Core Sale

The main article argued that year-end 2025 Cipia was no longer really an automotive vision story, but a company that had sold its core and was trying to cross into a different business before the remainder wore out. This follow-up isolates only that remainder: the economics of the aftermarket tail itself, stripped of the one-off disposal gain and separate from the broader Tomer thesis.

That matters because a superficial reading can still mistake the aftermarket activity for a lean residual software platform with optional upside. The filing points to something much narrower. What remained is a constrained sales window, limited to existing customers, with no material IP left at the company, a broader license bridge that already lapsed, extreme customer concentration, and Royaltek as the real production choke point. This is not an engine anymore. It is a tail.

What actually remained after the sale

The most important fact here is not the revenue line but the rights structure. The company states explicitly that after the asset sale it is no longer the owner of, and no longer holds usage rights in, material intellectual property for its activity. At the same time, the asset sale carved out the aftermarket activity around CIPIA FS-10, so the company kept that narrow business, but not the technological core that had defined the old story.

The second point, and the less obvious one, is that the broader license bridge never came into force. In parallel with the asset sale, the parties signed a license agreement that would have allowed the company to use the integrated IP embedded in the product, but only if an "approved merger and acquisition" had been completed by December 31, 2025. That did not happen, so the license expired and will not enter into force. In other words, investors who still assume Cipia retained a durable technology foothold are reading a path that never materialized.

What remained instead was much narrower:

That is the core distinction. The residual tail is not a smaller version of old Cipia. It is a limited commercial right to keep moving units to existing customers under clear contractual constraints. Even the ability to sell beyond the inherited window depends on both Red Bend and an added $11 per-unit royalty. This is not a platform the company kept. It is a shell that was allowed to keep moving a bit.

The tail economics: point-in-time sales, not a software engine

The 2025 economics of continuing operations sharpen that point. Cipia does not provide TSP services itself. It charges per unit sold. All continuing-operation revenue is recognized at a point in time. That sounds like dry accounting language, but the business meaning is simple: there is no subscription layer here, no recurring usage fee, and no revenue base that renews on its own. Every dollar has to come from another shipment.

And those shipments no longer look like a viable engine:

Continuing-operation revenue fell to $1.456 million in 2025 from $1.812 million in 2024. But the revenue decline is only the top layer of the story. Cost of revenue rose to $1.867 million, so gross profit of $352 thousand in 2024 turned into a gross loss of $411 thousand in 2025. Before G&A, before sales, before R&D, the residual tail was already failing the basic economic test.

What drove that? Not just ordinary demand erosion. Cost of revenue included a $725 thousand inventory-purchase obligation and a $117 thousand inventory write-down. That is not just routine production cost. It shows that even after the core sale, the residual business was still carrying inventory and procurement commitments built for an older operating model. In other words, part of the 2025 gross loss was not a weakening of a clean profitable business, but the residue of inventory decisions that survived after the original business had already been sold.

Even after deep cost cutting, the numbers still do not come together. R&D in continuing operations fell to $81 thousand, sales and marketing fell to $650 thousand, and G&A fell to $1.968 million. Taken together with the gross loss, that still leaves continuing operations with an operating loss of roughly $3.11 million. The company also says in the periodic report that it had not yet reached operating profitability in 2025, posted a current loss of about $3.3 million, and generated roughly $4 million of negative operating cash flow.

The conclusion is straightforward: the tail is not just small. It is not self-funding.

Cash and credit dynamics point the same way:

Average customer credit days were 155 in 2025, versus only 31 days from suppliers. Average customer credit stood at $1.274 million, while average supplier credit was only $159 thousand. Even after the scale-down, the company was still financing customers far more than suppliers were financing it. That matters because it breaks the idea that this is a light residual activity that can be carried almost without working capital.

Concentration: a narrow customer base getting narrower

If this model at least sat on a broad customer base, one could argue that Cipia retained a constrained but diversified distribution right. That is not what the filing shows. Since completion of the asset sale, the company says it sells only to existing customers. It names INTCOMEX and Tracking Hardware among the main customers, and in its concentration table it discloses that INTCOMEX alone accounted for 87% of 2025 revenue, with one additional customer contributing 10%.

That is no longer merely "high" concentration. It is close to an identity between the remaining business and one customer. And the next sentence in the filing makes the picture even sharper: end customers of CIPIA FS-10 are expected to decline because they are evaluating alternatives in light of the company’s reduced activity. So the customer base is not just narrow. It is thinning.

The issue runs deeper than the percentages. Cipia’s direct customers are TSPs and fleet-computing service providers, not the fleets themselves. The company does not provide TSP services. That means its access to the end market runs through an intermediate layer. When existing customers are already considering alternatives, Cipia is exposed not just to end demand, but to the willingness of a small number of distributors and integrators to keep backing a product from a company that has effectively shrunk itself.

The geography split shows how narrow the tail really is. Mexico alone contributed $1.271 million of the $1.456 million in 2025 revenue. That is another way of saying the residual activity is concentrated not just by customer, but by market.

Royaltek is the real bottleneck, not a footnote

On the supply side, the problem is concentrated in one name: Royaltek. The company describes Royaltek as a material supplier on which it depends for the development of the CIPIA FS-10. Royaltek also develops and manufactures the device for Cipia and charges a fixed price per unit. That already creates embedded dependence, but the filing adds two more troubling layers.

The first is that in 2022 the company placed a $2 million order with Royaltek to secure long-lead components, and at December 31, 2025 it still carried about $725 thousand of inventory tied to that procurement. So even before discussing fresh demand, part of the economics of the residual tail is still connected to components ordered in a very different commercial setup.

The second layer is more serious. On March 9, 2026 Royaltek notified the company of a component shortage and extended lead times from up to two months to at least three months, a delay that the company says does not allow it to meet customer requirements. The practical result, according to the filing, is that Cipia cannot produce additional units for customers and can sell only from existing inventory, which it says is immaterial.

That is worth pausing on. This is not just a supplier issue. It is the real test of the tail’s economics. Cipia still has a theoretical right to sell up to 9,000 units through June 30, 2026, and perhaps more beyond that subject to royalties and additional terms. But if lead times have stretched to a point that no longer fits customer requirements, and existing inventory is immaterial, then the contractual right to sell is no longer the same thing as the operational ability to monetize it. The paper option and the real economics have already diverged.

The company says it views Royaltek’s notice as a breach and is evaluating alternatives, but as of the filing there is no disclosed replacement supplier, no revised delivery schedule, and no locked-in solution. For now, Royaltek is not just another link in the chain. It is the neck through which the entire residual activity has to pass.

What this means for the right that remained

Put the pieces together and the residual picture is far narrower than the headline "aftermarket activity remained" suggests. There is still a product, there are still existing customers, there is still a sales window, and there is even a theoretical path to sell beyond 9,000 units. But almost every important component of that residual right is constrained:

And there is one more timing layer that makes the whole setup tighter. After the balance sheet date, the filing says Doron Kimlov, the intended controlling shareholder in the Tomer transaction, is not interested in the aftermarket activity and that, subject to completion of the deal, the activity will be terminated. So even in the scenario where Tomer closes, this tail is not presented as a business to keep building. It may simply be wound down.

That is why the right way to read Cipia’s residual aftermarket activity is not as a small but clean business. It is a declining bridge activity. The one-off $2.537 million disposal gain belongs to the sale of the discontinued operation. The economics that remained after that sale look very different: smaller revenue, a gross loss, long customer-credit terms, one-customer and one-supplier dependence, and a contractual window that becomes narrower precisely as the operational chain gets stuck.

Conclusion

Bottom line: what remained after the core sale was not a lean software company, but a time-limited and volume-limited right to sell hardware to existing customers, under worsening unit economics and only partial control over the value chain.

Put differently, the real question is not whether Cipia preserved an "aftermarket option." It is how much of that option is still monetizable in practice. Right now the cumulative answer from the filing is cautious: no material IP, no broader license in force, an $11 royalty on every unit beyond the inherited window, 87% of revenue coming from INTCOMEX, and Royaltek blocking supply. The residual tail looks far more like a slow exit path than a base for renewed growth.